MannKind Corporation (MNKD) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
30930 Russell Ranch Road
Danbury, CA 91362
United States of America (the)
Phone
818 661 5000
Website
Sector
Healthcare
Industry
Biotechnology
Employees
403
First IPO Date
July 28, 2004
| Name | Title | Pay | Year Born |
| Michael E. Castagna | Chief Executive Officer & Director | 1.61M | 1976 |
| Sanjay Singh | Executive Vice President of Technical Operations | 364,529 | 1966 |
| Dominic Marasco | President of Endocrine Business Unit | 717,723 | 1972 |
| Christopher Prentiss | Chief Financial Officer | 753,319 | 1975 |
| Stuart A. Tross | Chief People & Workplace Officer | 812,215 | 1967 |
| David Thomson | Executive Vice President, General Counsel & Secretary | 1.02M | 1967 |
| Ajay Ahuja | Executive VP & Chief Medical Officer | 0 | 1970 |
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.